Shell Asset Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$21K Sell
2,751
-963
-26% -$6.75K ﹤0.01% 1031
2025
Q2
$27K Sell
3,714
-418
-10% -$3.37K ﹤0.01% 1213
2025
Q1
$39K Sell
4,132
-183
-4% -$2.29K ﹤0.01% 1185
2024
Q4
$71K Sell
4,315
-40
-0.9% -$621 ﹤0.01% 1117
2024
Q3
$64K Buy
+4,355
New +$68.1K ﹤0.01% 1145
2024
Q1
$64K Sell
4,623
-556
-11% -$8.59K ﹤0.01% 1119
2023
Q4
$84K Sell
5,179
-1,504
-23% -$24.6K ﹤0.01% 1103
2023
Q3
$82K Sell
6,683
-103
-2% -$1.53K ﹤0.01% 1122
2023
Q2
$109K Sell
6,786
-41
-0.6% -$676 ﹤0.01% 1103
2023
Q1
$119K Sell
6,827
-23
-0.3% -$328 ﹤0.01% 1064
2022
Q4
$63K Sell
6,850
-531
-7% -$4.95K ﹤0.01% 1238
2022
Q3
$64K Sell
7,381
-948
-11% -$9.41K ﹤0.01% 1304
2022
Q2
$68K Buy
8,329
+109
+1% +$1.04K ﹤0.01% 1334
2022
Q1
$100K Sell
8,220
-1,230
-13% -$25.9K ﹤0.01% 1295
2021
Q4
$322K Buy
9,450
+5,786
+158% +$227K 0.01% 1083
2021
Q3
$177K Sell
3,664
-170
-4% -$7.87K ﹤0.01% 1224
2021
Q2
$173K Hold
3,834
﹤0.01% 1262
2021
Q1
$185K Buy
+3,834
New +$200K ﹤0.01% 1165

Other funds holding NEO

Shell Asset Management's NEO Position: Q3 2025 in Review

Shell Asset Management reduced its NeoGenomics (NEO) stake by 26% in Q3 2025, selling an estimated $6.75K and leaving 2,751 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #1031.

Shell Asset Management first reported a position in NEO in Q1 2021 and has held it in 18 quarters since. The position peaked at $322K in Q4 2021. 254 funds tracked by Wall St. Rank hold NEO as of Q3 2025.

  • Shell Asset Management held 2,751 shares of NeoGenomics worth $21K as of Q3 2025.
  • Shell Asset Management sold 963 NeoGenomics shares in Q3 2025, an estimated $6.75K.
  • NeoGenomics made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1031 holding.
  • Shell Asset Management first reported a position in NeoGenomics in Q1 2021 and has held it in 18 quarters since.
  • Shell Asset Management's NeoGenomics position peaked at $322K in Q4 2021.
  • 254 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.